RASGRP4 and diabetes mellitus: These findings indicate that the KO of RasGRP4 notably inhibited the IL-17 signaling pathway activation in the DI/R kidneys, thereby suppressing the expression of cytokines and chemokines and delaying the process of renal tissue remodeling, with diabetes serving as a risk factor for the aggravation of inflammatory damage.